Skip to main content
SpringerLink
Log in

Doxorubicin Chronotherapy in Japanese Outpatients with Breast Cancer

  • Short Communication
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Cresta S, Grasselli G, Mansutti M, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004; 15: 433–9

    Article  PubMed  CAS  Google Scholar 

  2. Hogberg T, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40: 340–60

    Article  PubMed  CAS  Google Scholar 

  3. Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncologica 2001; 40: 224–30

    Article  PubMed  CAS  Google Scholar 

  4. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145–53

    Article  PubMed  CAS  Google Scholar 

  5. Sparano JA, O’Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: eastern cooperative oncology group study E1196. J Clin Oncol 2000; 18: 2369–77

    PubMed  CAS  Google Scholar 

  6. To H, Kikuchi A, Tsuruoka S, et al. Time-dependent nephrotoxicity associated with daily administration of cisplatin in mice. J Pharm Pharmacol 2000; 52: 1499–504

    Article  PubMed  CAS  Google Scholar 

  7. Ohdo S, Koyanagi S, Suyama H, et al. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 2001; 7: 356–60

    Article  PubMed  CAS  Google Scholar 

  8. Matsunaga N, Nakamura N, Yoneda N, et al. Influence of feeding schedule on 24-hr rhythm of hepatotoxicity induced by acetaminophen in mice. J Pharmacol Exp Ther 2004; 311: 594–600

    Article  PubMed  CAS  Google Scholar 

  9. Ohdo S. Changes in toxicity and effectiveness with timing of drug administration. Drug Saf 2003, 26: 999–1010

    Article  PubMed  CAS  Google Scholar 

  10. Burns ER. Circadian biological time influences the effect adriamycin has on DNA synthesis in mouse bone marrow, ileum and tongue but not Ehrlich ascites carcinoma. Oncology 1985; 42: 384–7

    Article  PubMed  CAS  Google Scholar 

  11. Sothern RB, Levi F, Haus E, et al. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 1989; 81: 135–45

    Article  PubMed  CAS  Google Scholar 

  12. Granda TG, Filipski E, D’Attino RM, et al. Experimental chronotherapy of mouse breast adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 2001; 61: 1996–2001

    PubMed  CAS  Google Scholar 

  13. To H, Ohdo S, Shin M, et al. Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 2003; 55: 803–10

    Article  PubMed  CAS  Google Scholar 

  14. Canal P, Aqall A, de Forni M, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991; 40: 287–91

    Article  PubMed  CAS  Google Scholar 

  15. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science 1985; 228: 73–5

    Article  PubMed  CAS  Google Scholar 

  16. Barrett RJ, Blessing JA, Homesley HD, et al. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16: 494–6

    Article  PubMed  CAS  Google Scholar 

  17. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–79

    Article  PubMed  CAS  Google Scholar 

  18. von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7

    Google Scholar 

  19. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19: 314–21

    PubMed  CAS  Google Scholar 

  20. Labrecque G, Blelanger PM, Dore F, et al. 24 hour variations in the distribution of labeled microspheres to the intestine, liver and kidneys. Ann Rev Chronopharmacol 1988; 5: 445–8

    Google Scholar 

  21. Lemmer B, Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 1991; 32: 627–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

There was no external funding for this study. The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Clinical Pharmacokinetics, Division of Clinical Pharmacy, Department of Medico-Pharmaceutical Sciences Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, 815-8582, Japan

    Hideto To, Ohdo Shigehiro & Shun Higuchi

  2. Department of Surgery, Saitama Red Cross Hospital, Saitama, Japan

    Tsuyoshi Saito

  3. Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan

    Akio Fujimura

  4. Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan

    Eiji Kobayashi

Authors
  1. Hideto To
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsuyoshi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ohdo Shigehiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shun Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akio Fujimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiji Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideto To.

Rights and permissions

Reprints and permissions

About this article

Cite this article

To, H., Saito, T., Shigehiro, O. et al. Doxorubicin Chronotherapy in Japanese Outpatients with Breast Cancer. Drugs R D 6, 101–107 (2005). https://doi.org/10.2165/00126839-200506020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200506020-00005

Keywords

Search

Navigation